MANAGEMENT OF ENDOCRINE DISEASE: Personalized medicine in the treatment of acromegaly-Reference-Cited by-同舟云学术

MANAGEMENT OF ENDOCRINE DISEASE: Personalized medicine in the treatment of acromegaly

Published:2018-03 Issue:3 Volume:178 Page:R89-R100
ISSN:0804-4643
Container-title:European Journal of Endocrinology
language:
Short-container-title:

Author:

Kasuki Leandro¹²³,Wildemberg Luiz Eduardo¹²,Gadelha Mônica R¹²⁴

Affiliation:

1. 1Neuroendocrinology Research Center/Endocrine Section and Medical School, Hospital Universitário Clementino Fraga Filho, Universidade Federal do Rio de Janeiro, Rio de Janeiro, Brazil

2. 2Neuroendocrine Section, Instituto Estadual do Cérebro Paulo Niemeyer, Secretaria Estadual de Saúde do Rio de Janeiro, Rio de Janeiro, Brazil

3. 3Endocrine Unit, Hospital Federal de Bonsucesso, Rio de Janeiro, Brazil

4. 4Neuropathology and Molecular Genetics Laboratory, Instituto Estadual do Cérebro Paulo Niemeyer, Rio de Janeiro, Brazil

Abstract

Acromegaly is associated with high morbidity and elevated mortality when not adequately treated. Surgery is the first-line treatment for most patients as it is the only one that can lead to immediate cure. In patients who are not cured by surgery, treatment is currently based on a trial-and-error approach. First-generation somatostatin receptor ligands (fg-SRL) are initiated for most patients, although approximately 25% of patients present resistance to this drug class. Some biomarkers of treatment outcome are described in the literature, with the aim of categorizing patients into different groups to individualize their treatments using a personalized approach. In this review, we will discuss the current status of precision medicine for the treatment of acromegaly and future perspectives on the use of personalized medicine for this purpose.

Publisher

Bioscientifica

Subject

Endocrinology,General Medicine,Endocrinology, Diabetes and Metabolism

Reference224 articles.

1. The expression of E-cadherin in somatotroph pituitary adenomas is related to tumor size, invasiveness, and somatostatin analog response;Journal of Clinical Endocrinology and Metabolism,2010

2. Acromegaly;Endocrinology and Metabolism Clinics of North America,2008

3. Resistance to somatostatin analogs in acromegaly;Endocrine Reviews,2011

4. KasukiLVieira NetoLWildembergLEColliLMde CastroMTakiyaCMGadelhaMR AIP expression in sporadic somatotropinomas is a predictor of the response to octreotide LAR therapy independent of expression - Related https org;SSTR;Endocrine Cancer

5. In vitro head-to-head comparison between octreotide and pasireotide in gh-secreting pituitary adenomas;Journal of Clinical Endocrinology and Metabolism,2017

Cited by 59 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Artificial intelligence in endocrinology;Artificial Intelligence in Clinical Practice;2024

2. Current role of pasireotide in the treatment of acromegaly;Best Practice & Research Clinical Endocrinology & Metabolism;2024-01

3. Biomarkers of response to treatment in acromegaly;Expert Review of Endocrinology & Metabolism;2023-12-11

4. Using a precision approach to optimize the drug therapy of patients with acromegaly syndrome;The Pituitary Gland - An Overview of Pathophysiology and Current Management Techniques;2023-09-22

5. Pasireotide effects on biochemical control and glycometabolic profile in acromegaly patients switched from combination therapies or unconventional dosages of somatostatin analogs;Journal of Endocrinological Investigation;2023-09-11